KRYS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KR

Mkt Cap

$9.37B

Volume

177.66K

Next Earnings

November 2nd

Loading chart

KR

KRYSKrystal Biotech, Inc. Common Stock

KRYS

Pay with—

Available Balance0.00

KR

Mkt Cap

$9.77B

Volume

177.66K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.Zacks Investment Research · Oct 16, 2026

Krystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceKrystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.GlobeNewswire Inc. · Sep 3, 2026

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?Krystal Biotech shares have gained 12% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates with EPS of $1.79 vs. consensus of $1.70, and revenues of $119.2 million from Vyjuvek sales grew 24% year-over-year. Despite upward estimate revisions, the stock holds a Zacks Rank #3 (Hold) with an overall VGM Score of D, suggesting in-line returns ahead.Zacks Investment Research · Sep 2, 2026

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026Krystal Biotech announced it will report its second quarter 2026 financial results on August 3, 2026, with a conference call and webcast at 8:30 am ET. The company is a commercial-stage biotechnology firm focused on genetic medicines, with VYJUVEK® as its first commercial product—the first redosable gene therapy approved in the United States, Europe, and Japan for treating dystrophic epidermolysis bullosa.GlobeNewswire Inc. · Jul 23, 2026

Why Tutor Perini Stock Trounced the Market on TuesdayTutor Perini stock surged nearly 8% on Tuesday following news that it will be added to the S&P SmallCap 600 index. The construction company replaces Krystal Biotech in the index, which is itself moving up to the S&P MidCap 400 to fill the vacancy left by Taylor Morrison Home's acquisition by Berkshire Hathaway. The gain is primarily attributed to the 'index effect,' where index funds automatically purchase newly added constituents, though this has little impact on the company's fundamentals.The Motley Fool · Jul 21, 2026

3 Soaring Stocks That May Have More Upside AheadThe article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant market expansion opportunities. Marvell Technology is capitalizing on AI infrastructure spending demand for custom chips as an alternative to Nvidia's GPUs.The Motley Fool · Jul 7, 2026

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside AheadThree stocks—Moderna, Krystal Biotech, and AMD—have significantly outperformed the S&P 500 this year and are positioned for continued growth. Moderna is advancing toward approvals for its influenza and norovirus vaccines plus cancer vaccine candidates. Krystal Biotech's gene therapy Vyjuvek for rare skin disease is generating strong earnings with expansion opportunities. AMD is capitalizing on AI growth through its server CPU leadership and gaining market share from Intel.The Motley Fool · Jun 18, 2026

Krystal Biotech to Present at Upcoming Scientific ConferencesKrystal Biotech announced it will present on multiple gene therapy programs at scientific conferences in May and June 2026, including presentations on KB409/KB410 for primary ciliary dyskinesia at ASGCT, interim CORAL-1 trial results for KB407 in cystic fibrosis at ATS, and KB707 immunotherapy data at ASCO.GlobeNewswire Inc. · Apr 30, 2026

Is Vertex Pharmaceuticals' Empire in Trouble?Vertex Pharmaceuticals faces potential competition from newer cystic fibrosis drugs like Krystal Biotech's KB407 gene therapy, which could work for all CF patients versus Vertex's limited mutation coverage. However, the company's core franchise appears safe through the late 2030s due to patent exclusivity, and Vertex is actively diversifying its pipeline with approvals in gene editing and other therapeutic areas.The Motley Fool · Apr 16, 2026

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million InvestmentACT Capital Management invested $7.25 million in Viking Therapeutics, acquiring 206,100 shares. Viking, a clinical-stage biotech company, is developing obesity and metabolic disorder treatments, with its lead candidate VK2735 showing promising Phase 2 results of up to 14.7% weight reduction. The company has $706 million in cash runway and is advancing multiple clinical programs including Phase 3 trials.The Motley Fool · Mar 16, 2026

to start trading

KR

KRYSKrystal Biotech, Inc. Common Stock

KRYS

Pay with—

Available Balance0.00

Your PositionYou don't own any KRYS yet.

Related Tickers

Earnings